Opus Genetics Tags Rob Gagnon as Chief Financial Officer

RESEARCH TRIANGLE PARK, N.C.—Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small-molecule therapies for other ophthalmic disorders, has announced the appointment of Rob Gagnon, CPA, MBA, as chief financial officer (CFO), effective immediately. In making the announcement, the company noted Gagnon’s experience as a biotech executive with more than 20 years of financial and operational leadership experience in both public and private companies, as well as his senior roles guiding companies through IPOs, late-stage clinical development, commercial launches, and M&A.